Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics...
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, Aug. 18, 2023 STOCKHOLM, Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics...
Interim Report Q2, 2023: Calliditas Therapeutics PR Newswire STOCKHOLM, Aug. 17, 2023 Filing for full approval of TARPEYO STOCKHOLM, Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE...
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023 STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas...
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet PR Newswire STOCKHOLM, Aug. 15, 2023 STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas...
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM, July 13, 2023 STOCKHOLM, July 13, 2023...
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM, July 13, 2023 STOCKHOLM, July 13, 2023...
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM, June 21, 2023 STOCKHOLM, June 21, 2023...
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO® PR Newswire STOCKHOLM, June 21, 2023 STOCKHOLM, June 21, 2023...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, May 30, 2023 STOCKHOLM, May 30, 2023 /PRNewswire/ -- The following resolutions were passed at...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
